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CC BY-NC-ND license (http://creativeBackground/Purpose: Recent studies have shown that serum vitamin D deficiency is a negative
predictor of response to peginterferon plus ribavirin therapy for Caucasian patients with
chronic hepatitis C (CHC). Whether vitamin D receptor (VDR) gene polymorphisms associate
with antiviral response in Asian CHC patients remains unclear.
Methods: We recruited 139 Asian patients with CHC genotype-1 who achieved 80/80/80 adher-
ence of response-guided peginterferon plus ribavirin therapy. BsmI rs1544410, ApaI rs7975232,
and TaqI rs731236 were genotyped and related to clinical and virological features and to treat-
ment outcome.
Results: Patients carrying bAt [CCA] haplotype (pZ 0.033), ApaI CC genotype (pZ 0.033), and
TaqI AA genotype (p Z 0.037) had a higher HCV load as compared to those with other haplo-
types, ApaI CA/AA genotype and TaqI AG genotype, respectively. A sustained virological
response (SVR) was achieved in 74 (53%) of the patients. Polymorphisms in VDR gene did not
correlate with rapid virological response and SVR achievement. Stepwise logistic regression
analysis showed that rs12979860 CC type [odds ratio (OR): 5.56, pZ 0.007], platelet
counts  15  1010/L (OR: 4.80, pZ 0.001), and rapid virological response achievement
(OR: 8.36, p< 0.001) were independent factors of SVR.
Conclusion: Despite their associations with high hepatitis C virus load, VDR gene polymorphisms
are not related to the response to peginterferon plus ribavirin therapy in Asian CHC patients.
Copyright ª 2015, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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VDR polymorphisms and IFN response 279IntroductionHepatitis C virus (HCV) is one of the most common causes in
chronic infection resulting in liver cirrhosis and hepatocel-
lular carcinoma (HCC).1,2 The associated complications,
mortality, and need for liver transplantation are global
problems.3 Currently, the adjunction of new direct antiviral
agents is changing the therapeutic approach in chronic HCV
infection.4 However, a significant number of patients are
treated with the classic combination therapy of peginter-
feron and ribavirin where these new therapies cannot be
afforded.5e7 Consequently, to identify patients who are or
are not good candidates for peginterferon plus ribavirin
therapy is clinically important to avoid unnecessary treat-
ments and minimize adverse effects. Several factors prob-
ably affecting response to peginterferon plus ribavirin
therapy have been reported, including age,5e8 interleukin
(IL)28B polymorphisms,7,9,10 liver fibrosis,5e8 insulin resis-
tance,11 and viral factors, such as HCV load12 and HCV
variations.10
Vitamin D is involved in the metabolism of skeleton as a
systemic hormone but also has important roles in the
regulation of host immune responses, fibrogenesis, and
development of cancer through vitamin D receptor
(VDR).13e15 Interestingly, a recent study showed that lower
serum 25-hydroxylation (OH)D level was an independent
negative risk factor for sustained virological response (SVR)
to peginterferon plus ribavirin therapy for Caucasian pa-
tients with chronic hepatitis C.16 Other studies have also
reported that vitamin D supplementation may enhance the
antiviral response of peginterferon plus ribavirin
therapy,17e19 but controversy still exists.20,21 In addition,
VDR gene polymorphisms have been investigated in the
context of some chronic liver diseases, such as chronic
hepatitis B, primary biliary cirrhosis and autoimmune hep-
atitis.22e24 Another study has demonstrated that bioactive
1,25-di-(OH)D3 enhanced the inhibitory effect of inter-
feron-a on HCV replication, and has identified the VDR as a
novel suppressor of interferon-a-induced signaling through
the JakeSTAT pathway.25
So far, there are limited data on the association between
VDR polymorphisms and the antiviral response in chronic
hepatitis C. In this study, we conducted a cohort of chronic
hepatitis C patients in Asia receiving response-guided
therapy with peginterferon plus ribavirin to clarify this
issue.
Methods
Patients
From August 2011 to July 2013, a total of 151 naive patients
with chronic HCV genotype-1 infection who received
peginterferon plus ribavirin therapy in single medical cen-
ter in Taiwan were enrolled. All patients were seropositive
for HCV antibody and HCV RNA, and all had exhibited
elevated alanine aminotransferase levels. Patients were
excluded if they were positive for serum hepatitis B surface
antigen or anti-human immunodeficiency virus antibody, or
exhibited other causes of hepatocellular injury (e.g., any
history of alcoholism, autoimmune hepatitis, primarybiliary cirrhosis, or treatment with hepatotoxic drugs).
Clinical diagnosis of cirrhosis was based on repeated ul-
trasound findings suggestive of cirrhosis at least twice
3 months apart, supplemented with clinical criteria or
other signs of portal hypertension.26 In these 151 patients,
we excluded 12 patients who did not fit the 80/80/80
adherence rule (< 80% of total peginterferon or ribavirin
doses or < 80% of the total duration of therapy), with a final
case number of 139.
Patients were treated according to the on-treatment
response as follows: 24 weeks for patients achieving a rapid
virological response (RVR, seronegativity of HCV RNA at
4 weeks of therapy); 48 weeks for those with an early
virological response (EVR, at least a 2 e log10 decrease
from baseline of serum HCV RNA at 12 weeks of treatment);
and early termination (< 16 weeks) in those without an
EVR. This protocol has been recommended by the National
Health Insurance Bureau in Taiwan since November 2009.
All patients received either peginterferon a-2a (180 mg/
week) or peginterferon a-2b (1.5 mg/kg/wk) subcutaneously
plus weight-based ribavirin (1000 mg/d for weight < 75 kg
and 1200 mg/d for weight > 75 kg). The endpoint of the
study was achievement of a SVR, defined as seronegativity
of HCV RNA throughout 24 weeks of post-treatment follow-
up period. The study protocol conformed to the ethical
guidelines of the 1975 Declaration of Helsinki and was
approved by the Institutional Review Board of the hospital.
Qualitative and quantitative assay of HCV-RNA and
HCV genotyping
Serum was prepared in a laminar flow bench and frozen at
70C until use. Before treatment, qualitative detection of
HCV RNA was performed by a standardized qualitative
reverse transcriptionepolymerase chain reaction (PCR)
assay (Amplicor; Roche Diagnostics, Branchburg, NJ, USA),
using biotinylated primers for the 50 noncoding region. The
lowest detection limit of this assay was 50 IU/mL. Serum
HCV RNA levels were determined by COBAS TaqMan HCV
Test (TaqMan HCV; Roche Molecular Systems Inc., Branch-
burg, NJ, USA; lower limit of detection: 15 IU/mL). Geno-
typing of HCV was performed by reverse hybridization assay
(Inno-LiPA HCV II; Innogenetics N.V., Gent, Belgium) using
the HCV-Amplicor products.
Detection of VDR and IL28B polymorphisms
The DNA was extracted from peripheral blood leukocytes
using the Qiagen DNA isolation kit (Qiagen, Hilden, Ger-
many). The VDR genotype was determined by PCR amplifi-
cation and restriction length fragment polymorphisms as
previously described.25 For the detection of BsmI poly-
morphisms, a forward primer in exon 7 (50-CAACCAA-
GACTCAAGTACCGCGTCAGTGA-30) and a reverse primer in
intron 8 (50-AACCAGCGGAAGAGGTCAAGGG-30) were used.
For the detection of ApaI and TaqI polymorphisms, a for-
ward primer in exon 8 (50-CAGAGCATGGACAGGGAGCAA-30)
and a reverse primer in exon 9 (50-GCAACTCCTCATGGCT-
GAGGTCTC-30) were used. The PCR products for BsmI
polymorphisms were 820 base pairs (bp), and for ApaI/TaqI
polymorphisms they were 745 bp. The PCR mix contained
Table 1 Baseline characteristics of the study population.
Variables (nZ 139)
Age (y) 56 (47e61)
Sex (male/female) 71/68
rs12979860 (CC/CT or TT) 113/26
LC (%) 19 (14)
BMI (kg/m2) 25 (23e27)
Log HCV-RNA (IU/mL) 6.0 (5.3e6.5)
Genotype 1a/1b/1 2/116/21
AST (U/L) 61 (42e92)
ALT (U/L) 82 (51e120)
Platelets (1010/L) 18 (13e22)
Data are expressed as median (interquartile range) or n (%).
ALT Z alanine transaminase; AST Z aspartate transaminase;
BMI Z body mass index; HCV Z hepatitis C virus; LC Z liver
cirrhosis.
280 C.-H. Hung et al.5 mL of each primer (10 pmol), 5 mL buffer, 1.5 mL MgCl2
(50mM), 5 mL template DNA (50e100 ng), 5 mL dNTPs (2mM),
Taq polymerase (MBI Fermentas, St. Leon-Rot, Germany)
2 mL, H2O 26.5 mL. The DNA template was denatured at 95
C
for 2 minutes. A total of 40 cycles of PCR were performed,
consisting of a denaturation step for 45 seconds at 94C, an
annealing step for 45 seconds at optimum temperature
(67C for ApaI/TaqI and 60C for BsmI), and an extension
reaction for 1 minute at 72C. A final extension step at 72C
for 2 minutes was added after the last PCR cycle.
After amplification, the PCR products were digested
with BsmI, ApaI, and TaqI endonucleases. Following re-
striction endonuclease digestion, genotyping was deter-
mined by ethidium bromide-UVB illumination of the
fragments separated on gels of 2% agarose. The presence of
BsmI, ApaI, or TaqI restriction sites was defined as the
lower-case “b”, “a”, or “t”, respectively, and the absence
of the sites defined as the upper-case “B”, “A”, or “T”. TheTable 2 Comparison between bAt[CCA]-haplotype and
other haplotypes.
CCA-haplotype
(n Z 76)
Other
haplotypes
(n Z 63)
p
Age (y) 55 (46e61) 57 (48e61) 0.519
Male (%) 41 (54) 30 (48) 0.284
BMI (kg/m2) 25 (23e27) 24 (21e28) 0.362
LC 11 (14) 8 (13) 0.480
rs12979860 CC type 60 (79) 53 (84) 0.289
AST (U/L) 59 (42e90) 64 (41e94) 0.462
ALT (U/L) 79 (50e110) 94 (51e128) 0.361
Platelets (1010/L) 18 (13e21) 19 (14e22) 0.243
Log HCVeRNA (IU/ml) 6.2 (5.6e6.6) 5.8 (5.2e6.4) 0.033
Data are expressed as median (interquartile range) or n (%); p-
value by ManneWhitney U test or c2 test.
ALT, alanine transaminase; AST Z aspartate transaminase;
BMI Z body mass index; HCV Z hepatitis C virus; LC Z liver
cirrhosis.BsmI restriction site resulted in two fragments (645 bp and
177 bp). Digestion with ApaI produced two fragments of
531 bp and 214 bp when the restriction site was present.
Digestion with TaqI resulted in three fragments of approx-
imately 205 bp, 290 bp, and 245 bp in the presence of TaqI
polymorphic site, and in fragments of 245 bp and 495 bp in
its absence.
IL28B variant rs12979860C>T was diagnosed from stored
samples using direct sequencing (AmpliTaq gold DNA poly-
merase and BigDye terminator v1.1 cycle sequencing kit;
Applied Biosystems, Warrington, Cheshire, UK). The PCR
products were separated on an ABI3130 sequencer, and
analyzed with SEQSCAPE 2.6 (Applied Biosystems). Primers
for amplification were: forward primer: 50-ATTCCTG-
GACGTGGATGGGTACT-30, reverse primer: 50-biotin-GGAG
CGCGGAGTGCAATT-30. The sequencing primer required for
the detection of a short DNA sequence around the SNP of
interest was 50-AGCTCCCCGAAGGCG-30.Statistical analysis
Continuous data are expressed as mean  standard devia-
tion, and the categorical data are expressed as number
(percentage). Comparisons of differences in categorical
date between groups were performed using the Chi-square
test. Distributions of continuous variables were analyzed by
the Student t test or ManneWhitney U test for the two
groups where appropriate. Independent factors possibly
affecting response to peginterferon plus ribavirin therapy
were determined by stepwise multiple logistic regression
analysis. A p value < 0.05 was considered statistically
significant.Results
Baseline characteristics
The basic demographic, virologic, and clinical features of
the patients are shown in Table 1. There were 71 men and
68 women, age 20e78 years (mean, 56 years). Fourteen
percent (nZ 19) of patients had cirrhosis. Of these pa-
tients, 43 (31%) patients achieved a RVR, 87 (62.6%) ach-
ieved an EVR without RVR and nine (6.4%) had no EVR. The
rates of SVR were 84% (nZ 36) of RVR patients, 44%
(nZ 38) of EVR patients and 0% of non-EVR patients,
respectively.Comparison between bAt [CCA]-haplotype and
other haplotypes
Of these patients, 76 (55%) carried bAt [CCA] haplotype. As
shown in Table 2, univariate analysis revealed that only
HCV viral load was significantly different between these
two groups. Figure 1 shows the association of VDR genotype
with HCV load. We found that the carriage of ApaI CC ge-
notype and TaqI AA genotype had significant higher viral
load as compared to those with ApaI CA/AA type and TaqI
AG type, respectively.
Figure 1 Association of VDR gene polymorphisms with viral load in chronic HCV infection. BsmI (pZ 0.371), ApaI (pZ 0.033), and
TaqI (pZ 0.037).
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response to peginterferon plus ribavirin in a
response-guided therapy
As shown in Figure 2, patients carrying the bAt [CCA]
haplotype, ApaI CC genotype, and TaqI AA genotype had a
trend in lower rate of achieving RVR and SVR. However,
there were no significant associations of VDR gene poly-
morphisms with RVR and SVR achievement. By univariate
analysis, the carriage of rs12979860 CC genotype, cirrhosis,
higher platelet counts, and RVR were significantly associ-
ated with SVR. Stepwise logistic regression analysis
revealed that rs12979860 CC genotype, higher platelet
counts and RVR were independent predictors of SVR among
these patients (Table 3).Figure 2 Associations of VDR gene polymorphismsDiscussion
Experimental evidence suggests the potential ability of
vitamin D, through interaction with VDR, to regulate the host
immune responses, fibrogenesis, and carcinogenesis.13e15
One of the common genetic variations of VDR gene is the
bAt haplotype consisting of three adjacent restriction poly-
morphic sites, BsmI, ApaI, and TaqI.27,28 These genetic var-
iations have been described as important modulators of
several chronic liver diseases such as primary biliary cirrhosis
and autoimmune hepatitis.23,24 In addition, our previous
data showed that chronic hepatitis C patients with HCC had a
higher frequency of ApaI CC genotype and bAt [CCA] haplo-
type than controls, and ApaI C polymorphism might be used
as a molecular marker to predict the risk of HCC.29 In thiswith RVR and SVR achievement (all p > 0.05).
Table 3 Factors associated with sustained virological response to peginterferon plus ribavirin in a responseeguided therapy.
Univariate analyses Stepwise multivariate analyses
Odds ratio (95% CI) p Odds ratio (95% CI) p
Age  55 y 0.673 (0.344e1.318) 0.248 d d
Male 1.149 (0.590e2.239) 0.683 d d
BMI  25 kg/m2 1.383 (0.709e2.700) 0.342 d d
rs12979860 CC type 6.586 (2.314e18.75) <0.001 5.562 (1.603e19.30) 0.007
BsmI CC type 1.148 (0.275e4.785) 0.850
ApaI CC type 0.843 (0.431e1.648) 0.618
TaqI AA type 0.668 (0.153e2.910) 0.591
CCA haplotype 0.843 (0.431e1.648) 0.618
Cirrhosis 0.264 (0.089e0.780) 0.016 d d
Platelets  15  1010/L 3.683 (1.706e7.952) 0.001 4.797 (1.880e12.24) 0.001
HCV RNA  4  105 IU/mL 1.066 (0.525e2.163) 0.860 d d
RVR 7.850 (3.169e19.44) < 0.001 8.362 (2.908e24.04) < 0.001
BMI Z body mass index; CI Z confidence interval; RVR Z rapid virological response.
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type, ApaI CC genotype, and TaqI AA genotype with higher
HCV load. Although the detailed mechanisms remain to be
clarified, these observations could be explained by the
immunomodulatory effects of vitamin D, and thus poly-
morphisms in VDR could affect the host response against
HCV.
Two recent studies have reported that the VDR bAt [CCA]
haplotype impairs antiviral response to peginterferon plus
ribavirin therapy in Caucasian patients with chronic hepa-
titis C.30,31 By contrast, we failed to find a significant as-
sociation between VDR gene polymorphisms and treatment
response, although there was a trend in lower rate of SVR
among patients carrying bAt [CCA] haplotype, ApaI CC ge-
notype, and TaqI AA genotype. These discordant results
might be associated with the following facts. First, the C
allele of the IL-28B rs12979860 C/T polymorphism is much
more prevalent in Asians than in Caucasians,32 and patients
with IL28B favorable genotype attain a high SVR rate up to
70e80% in genotype-1 chronic hepatitis C patients.10,33
Therefore, it is possible that the high prevalence of the C
allele results in blunting of the effect by vitamin D. This
possibility is supported by the finding that a group of
Caucasian patients with IL28B favorable genotype who had
higher 25(OH)D concentrations had an SVR rate of 85.7%,
whereas those with IL28B unfavorable genotype who also
had higher 25(OH)D concentrations had an SVR rate of only
36.8%.34 Second, it is well established that there are racial
differences in the relations between the 25(OH)D concen-
trations, parathyroid hormone concentration, and calcium
homeostasis.35 Racial differences in vitamin D physiology or
race-specific factors that modify the effects of vitamin D
may affect the immune response to HCV.36 Further studies
with an increased number of cases are necessary to reach a
firm conclusion.
A number of studies have evaluated an association be-
tween baseline 25(OH)D level and SVR to peginterferon plus
ribavirin therapy in chronic HCV infection.16e21,34,35 How-
ever, studies have yielded inconsistent results because of
variation in the 25(OH)D assay used, and the different
ethnicities and geographic latitude of populations stud-
ied.16e21,34,35 In our study, the retrospective designprecluded us to determine serum vitamin D and hence to
analyze the possible influence of the studied poly-
morphisms on serum concentrations of vitamin D. However,
this could be justified since VDR gene variants modulate
biological effects of vitamin D without influencing serum
vitamin D levels.28,37 In addition, serum 25(OH)D levels
strongly fluctuate during seasons, with age, and as a
consequence of numerous other conditions.13,38
In conclusion, the present study suggests a significant
association of VDR bAt [CCA]-haplotype, ApaI CC genotype,
and TaqI AA genotype with higher viral load in Asian pa-
tients with chronic HCV infection. However, VDR gene
polymorphisms are not related to the response to pegin-
terferon plus ribavirin therapy in our study population. The
detailed molecular mechanisms deserve further
investigation.Acknowledgments
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